G1 reaffirmed its full year 2024 COSELA net revenue guidance and updated its cash runway guidance. G1’s guidance is based on current expectations for continued sales growth of COSELA in the U.S. and achievement of its forecasts. The company expects to generate between $60M-$70M in COSELA net revenue in 2024. Additionally, G1 plans to wind down the Phase 3 PRESERVE 2 trial, discontinue the anticipated hiring of staff and investment for a 1L TNBC indication and make targeted headcount reductions outside of the existing commercial organization to streamline the company. These efforts are expected to provide sufficient cash runway to achieve anticipated company profitability in the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics participates in a conference call with JPMorgan
- G1 Therapeutics announces inducement grants under Nasdaq listing rule
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics’ trilaciclib combiation improves breast cancer overall survival
- Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)